-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

If you suffered a loss as a result of Vanda's misconduct, click here.

Vanda Pharmaceuticals Used its Drugs for Off-Label Purposes

For years, Vanda and its officers hid that Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs and that Vanda's promotional materials were false and misleading, garnering scrutiny from the FDA. Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies. Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. Vanda also issued misleading statements regard tradipitant's clinical trials with the FDA. When the truth was revealed, Vanda's stock declined over 5% and has slipped even more, now trading at just around $11.00. As a result of this conduct, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation. Vanda has also been named as a defendant in a securities class action lawsuit, causing further damage to the company.

Vanda Pharmaceuticals Inc. (VNDA) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. For be notified if a class action against Vanda Pharmaceuticals settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Alight, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Alight, Inc. (NYSE: ALIT) common stock between November 12, 2024 and February 18, 2026. Alight is predominantly an employee benefits solutions company that provides technology-enabled services to employees through the Alight Worklife cloud engagement platform. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a c...

Investor Notice: Robbins LLP Informs Investors of the ChowChow Cloud International Holdings Limited Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ChowChow Cloud International Holdings Limited (NYSE: CHOW) securities between September 16, 2025 and December 10, 2025. CHOW, through its subsidiaries, provides cloud solutions to businesses in Hong Kong, Singapore, the Philippines, Taiwan, Indonesia, and Australia. For more information, submit a form, email attorney Aaron Dumas, Jr., or give...

Investor Notice: Robbins LLP Informs Investors of the Trip.com Group Limited Class Action Lawsuit

SAN DIEGO, Calif.--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Trip.com Group Limited (NASDAQ: TCOM) American Depository Shares ("ADS") between April 30, 2025 and January 13, 2026. Trip.com claims to be a leading global one-stop travel service provider, integrating a comprehensive suite of travel products and services and differentiated travel content. For more information, submit a form, email at...
Back to Newsroom